2016版美国甲状腺协会《甲状腺功能亢进症和其他原因所致甲状腺毒症诊治指南》解读：核医学部分  

Interpretation of 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis： nuclear medicine part

作　　者：蒋宁一[1] Jiang Ningyi(Department of Nuclear Medicine, Sun Yet-Sen Memorial Hospital, Sun Yet-Sen University, Guangzhou 510289, China)

机构地区：[1]中山大学孙逸仙纪念医院核医学科,广州510289

出　　处：《中华核医学与分子影像杂志》2018年第5期305-310,共6页Chinese Journal of Nuclear Medicine and Molecular Imaging

摘　　要：2016年美国甲状腺协会（ATA）新版《甲状腺功能亢进症和其他原因所致甲状腺毒症诊治指南》中循证推荐数目增至124个（2011版指南中有100个），更加细化了甲状腺疾病的诊断、治疗方案。^131I为治疗格雷夫斯病（GD）的一种重要方法，新版指南中对其作了详尽的叙述，包括应用指征、剂量确定、防护措施及在儿童中合理应用等。该文对新版指南中核医学部分内容进行解读，重点解读其中更新的内容。The new American Thyroid Association （ATA） guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis was published in 2016. Compared to the 100 pieces of evidence-based recommendations in 2011 edition guidelines, the 2016 edition guidelines included 124 pieces of evidence-based recommendations, which made the diagnosis and therapy of thyroid diseases more detailed. As one of the most important treatment for Graves disease （GD）, ^131I therapy was explained more completely in the 2016 edition guidelines, including the indication, the determination of dose, the radiation protection, the reasonable application in children and so on. The purpose of this paper is to interpret the 2016 edition guidelines about the diagnosis and therapy of thyroid diseases in the view of nuclear medicine, focusing on the updated contents.

关 键 词：甲状腺毒症 甲状腺功能亢进症 实践指南 核医学 美国 

分 类 号：R581[医药卫生—内分泌]